Semaglutide vs Tesofensine
An approved drug with pivotal trials and a cardiovascular outcomes result against a single flagged Phase 2 number that was never confirmed. The evidence gap is the comparison.
Semaglutide
Wegovy / Ozempic
~15% mean weight loss in STEP 1; the benchmark that opened modern obesity medicine.
Full Semaglutide evidence reviewTesofensine
A triple monoamine reuptake inhibitor with ~9% Phase 2 weight loss — but flagged by a Lancet Expression of Concern, with no Phase 3 and no approval.
Full Tesofensine evidence reviewSide by side
| Semaglutide | Tesofensine | |
|---|---|---|
| Marketed for | Weight loss, type-2 diabetes | Weight loss (marketed alongside GLP-1s) |
| Evidence grade | FDA-approved | Clinical data |
| Family | GLP-1 / incretin | GLP-1 / incretin |
| Regulatory status | FDA-approved | Investigational |
| How it's obtained | Rx product | Research-only |
| Key human source | STEP 1, NEJM 2021 | Astrup, Lancet 2008 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
This one is not close. Semaglutide is approved, cut mean body weight by about 14.9% in STEP 1, and reduced major adverse cardiovascular events by roughly 20% in SELECT. Tesofensine is an investigational triple monoamine reuptake inhibitor; its headline 9.2% at the 0.5 mg dose comes from one 24-week Phase 2 trial that later received a Lancet Expression of Concern, there is no completed Phase 3, and it is not approved. It also raised heart rate by 7.4 beats per minute at that dose, a stimulant-class signal rather than an incretin one. The two have never been compared directly, and given the state of the tesofensine record they are not really comparable.
Semaglutide fits if
You want a weight-loss drug with pivotal trials, an approval, and hard cardiovascular outcome data.
Tesofensine fits if
There is no treatment case here; tesofensine is worth reading only if you follow unsettled obesity pharmacology and want to understand why a striking Phase 2 result never became a drug.
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm Tesofensine availability before ordering.
